AB Science
AB
Company Profile
Business description
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
Contact
3, Avenue George V
Paris75008
FRAT: +33 147200014
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
39
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 66.30 | -0.71% |
| CAC 40 | 7,843.04 | 126.65 | -1.59% |
| DAX 40 | 24,273.12 | 89.97 | -0.37% |
| Dow JONES (US) | 45,397.85 | 233.89 | -0.51% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 490.77 | 1.94% |
| NASDAQ | 21,554.31 | 57.78 | 0.27% |
| Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
| NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
| S&P 500 | 6,463.33 | 3.58 | -0.06% |
| S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |